Clinical Trial

IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 30, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a multicenter, open-label, single-arm, phase Ib/II clinical study comprising two phases: dose confirmation phase and dose expansion phase. The objective of the dose confirmation phase is to determine the recommended Phase II dose (RP2D) of IN10018+ standard chemotherapy (albumin-bound paclitaxel + gemcitabine) and IN10018 + KN046 + standard chemotherapy in subjects with advanced pancreatic cancer. The dose expansion phase will further explore the antitumor activities and safety of combination therapy in subjects with advanced pancreatic cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-04-23.
Trial Details
NCT Number NCT05827796
Lead Sponsor InxMed (Shanghai) Co., Ltd.
Conditions Pancreatic Cancer
Enrollment 70 participants
Start Date 2022-12-08
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-30